Clinical Pharmacokinetics

, Volume 45, Issue 6, pp 543–566 | Cite as

Transdermal Scopolamine for Prevention of Motion Sickness

Clinical Pharmacokinetics and Therapeutic Applications
  • Zohar NachumEmail author
  • Avi Shupak
  • Carlos R. Gordon
Review Article


A transdermal therapeutic system for scopolamine (TTS-S) was developed to counter the adverse effects and short duration of action that has restricted the usefulness of scopolamine when administered orally or parenterally. The plaster contains a reservoir of 1.5mg of scopolamine programmed to deliver 0.5mg over a 3-day period. A priming dose (140μg) is incorporated into the adhesive layer to saturate certain binding sites within the skin and to accelerate the achievement of steady-state blood levels. The remainder is released at a constant rate of approximately 5 μg/hour. The protective plasma concentration of scopolamine is estimated to be 50 pg/mL. TTS-S attains that concentration after 6 hours; a steady state of about 100 pg/mL is achieved 8–12 hours after application. Yet 20–30% of subjects failed to attain the estimated protective concentration, and plasma concentrations measured in subjects who failed to respond to TTS-S were lower than in responders. These findings may explain some of the treatment failures. Overall, the product appears to be the approximate functional equivalent of a 72-hour slow intravenous infusion. A combination of transdermal and oral scopolamine (0.3 or 0.6mg) was effective and well tolerated in producing desired plasma concentrations 1-hour post-treatment.

TTS-S has proved to be significantly superior to placebo in reducing the incidence and severity of motion sickness by 60–80%. It was more effective than oral meclizine or cinnarizine, similar to oral scopolamine 0.6mg or promethazine plus ephedrine, and the same as or superior to dimenhydrinate. The addition of ephedrine or the use of two patches did not improve its efficacy, but rather increased the rate of adverse effects. TTS-S was most effective against motion sickness 8–12 hours after application. Despite previous evidence to the contrary, a recent bioavailability study demonstrated similar intraindividual absorption and sustained clinical efficacy with long-term use of the drug.

The adverse effects produced by TTS-S, although less frequent, are qualitatively typical of those reported for the oral and parenteral formulations of this agent. Dry mouth occurs in about 50–60% of subjects, drowsiness in up to 20%, and allergic contact dermatitis in 10%. Transient impairment of ocular accommodation has also been observed, in some cases possibly the result of finger-to-eye contamination. Low-dose pyridostigmine was found effective in preventing cycloplegia but not mydriasis. Adverse CNS effects, including toxic psychosis (mainly in elderly and paediatric patients), have been reported only occasionally, as have difficulty in urinating, headache, rashes and erythema. Adverse effects were not correlated with plasma scopolamine concentrations. TTS-S produced only about half the incidence of drowsiness caused by oral dimenhydrinate or cinnarizine, and a level of adverse effects similar to that found with oral meclizine. Performance is not affected by short-term use. Prolonged or repeated application may cause some impairment of memory storage for new information. However, sea studies revealed significantly less reports of a decrement in performance or drowsiness due to prevention of sea sickness.

The recommended dosage is a single TTS-S patch applied to the postauricular area at least 6–8 hours before the anti-motion sickness effect is required. For faster protection, the patch may be applied 1 hour before the journey in combination with oral scopolamine (0.3 or 0.6mg). After 72 hours, the patch should be removed and a new one applied behind the opposite ear. Its place in therapy is mainly on long journeys (6–12 hours or longer), to avoid repeated oral doses, or when oral therapy is ineffective or intolerable.


Scopolamine Motion Sickness Allergic Contact Dermatitis Cinnarizine Urinary Excretion Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors are grateful to Mr Richard Lincoln for his assistance in the preparation of the manuscript.

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Reason JT, Brand JJ. Motion sickness. London: Academic Press, 1975Google Scholar
  2. 2.
    Rolnick A, Gordon CR. The effects of motion induced sickness on military performance. In: Gal R, Mangelsdorff AD, editors. Handbook of military psychology. Chichester: John Wiley & Sons Ltd, 1991: 279–93Google Scholar
  3. 3.
    Gordon CR, Spitzer O, Doweck I, et al. Clinical features of mal de debarquement: adaptation and habituation to sea conditions. J Vestib Res 1995; 5: 363–9PubMedGoogle Scholar
  4. 4.
    Kennedy RS, Fowlkes JE, Lilienthal MG. Postural and performance changes following exposures to flight simulators. Aviat Space Environ Med 1993; 64: 912–20PubMedGoogle Scholar
  5. 5.
    Gordon CR, Shupak A. Prevention and treatment of motion sickness in children. CNS Drugs 1999; 12: 369–81Google Scholar
  6. 6.
    Wood CD, Graybiel A. A theory of motion sickness based on pharmacological reactions. Clin Pharmacol Ther 1970; 11: 621–9PubMedGoogle Scholar
  7. 7.
    Takeda N, Morita M, Hasegawa S, et al. Neuropharmacology of motion sickness and emesis: a review. Acta Otolaryngol Suppl 1993; 501: 10–5PubMedGoogle Scholar
  8. 8.
    Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s: the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 141–60Google Scholar
  9. 9.
    Parrott AC. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med 1989; 60: 1–9PubMedGoogle Scholar
  10. 10.
    Shaw JE. Development of transdermal therapeutic systems. Drug Dev Ind Pharm 1983; 9: 579–603Google Scholar
  11. 11.
    Chandrasekaran SK. Controlled release of scopolamine for prophylaxis of motion sickness. Drug Dev Ind Pharm 1983; 9: 627–46Google Scholar
  12. 12.
    Graybiel A. Prevention and treatment of space sickness in shuttle-orbiter missions. Aviat Space Environ Med 1979; 50: 171–6PubMedGoogle Scholar
  13. 13.
    Graybiel A, Knepton J, Shaw J. Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat Space Environ Med 1976; 47: 1096–100PubMedGoogle Scholar
  14. 14.
    Graybiel A, Cramer DB, Wood CD. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat Space Environ Med 1982; 53: 770–2PubMedGoogle Scholar
  15. 15.
    Clissold SP, Heel RC. Transdermal hyoscine (scopolamine): a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 189–207PubMedGoogle Scholar
  16. 16.
    Shaw JE, Chandrasekaran SK. Transdermal therapeutic systems. In: Prescott LF, Nimmo WS, editors. Drug absorption: the proceedings of the Edinburgh International Conference on Drug Absorption, 1979. Balgowlah: ADIS Press, 1981: 186–93Google Scholar
  17. 17.
    Chandrasekaran SK, Bayne W, Shaw JE. Pharmacokinetics of drug permeation through human skin. J Pharm Sci 1978; 67: 1370–4PubMedGoogle Scholar
  18. 18.
    Shaw JE, Chandrasekaran SK, Campbell PS, et al. New procedures for evaluating cutaneous absorption. In: Drill VA, Lazar P, editors. Cutaneous toxicity. Proceedings of the 3rd Conference of the American Medical Association; 1976 May 16-18; Washington, DC. New York (NY): Academic Press, 1977: 83–94Google Scholar
  19. 19.
    Shaw JE, Chandrasekaran SK. Controlled topical delivery of drugs for systemic action. Drug Metab Rev 1978; 8: 223–33PubMedGoogle Scholar
  20. 20.
    Pyykko I, Schalen L, Jantti V. Transdermally administered scopolamine vs dimenhydrinate I: effect on nausea and vertigo in experimentally induced motion sickness. Acta Otolaryngol 1985; 99: 588–96PubMedGoogle Scholar
  21. 21.
    Homick JL, Kohl RL, Reschke MF, et al. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat Space Environ Med 1983; 54: 994–1000PubMedGoogle Scholar
  22. 22.
    Parrott AC, Jones R. Effects of transdermal scopolamine upon psychological test performance at sea. Eur J Clin Pharmacol 1985; 28: 419–23PubMedGoogle Scholar
  23. 23.
    Graybiel A, Cramer DB, Wood CD. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine. Aviat Space Environ Med 1981; 52: 337–9PubMedGoogle Scholar
  24. 24.
    Shaw J, Urquhart J. Programmed, systemic drug delivery by the transdermal route. Trends Pharmacol Sci 1980; 1: 208–11Google Scholar
  25. 25.
    Urquhart J. Rate-controlled drug dosage. Drugs 1982; 23: 207–26PubMedGoogle Scholar
  26. 26.
    Guy RH, Hadgraft J. Interpretation and prediction of the kinetics of transdermal drug delivery: oestradiol, hyoscine and timolol. Int J Pharm 1986; 32: 159–63Google Scholar
  27. 27.
    Vollmer U, Muller BW, Wilffert B, et al. An improved model for studies on transdermal drug absorption in-vivo in rats. J Pharm Pharmacol 1993; 45: 242–5PubMedGoogle Scholar
  28. 28.
    Haley TJ. Scopolamine or hyoscine: chemical review. Danger Prop Ind Mater Rep 1982; 3: 16–8Google Scholar
  29. 29.
    Scheurlen M, Bittiger H, Ammann B. Simple radioligand binding assay for the determination of urinary scopolamine. J Pharm Sci 1984; 73: 561–3PubMedGoogle Scholar
  30. 30.
    Shaw JE, Chandrasekaran SK, Taskovich L. Use of percutaneous absorption for systemic administration of drugs. Pharm J 1975; 215: 325–8Google Scholar
  31. 31.
    Muir C, Metcalfe R. A comparison of plasma levels of hyoscine after oral and transdermal administration. J Pharm Biomed Anal 1983; 1: 363–7PubMedGoogle Scholar
  32. 32.
    Ensing K, de Zeeuw RA, Ensing GJ. Pharmacokinetics of free and glucuronidated scopolamine following transdermal delivery of scopolamine in children [abstract]. Acta Pharmacol Toxicol Copenh 1986; 59 Suppl. 5: 81Google Scholar
  33. 33.
    Ensing K, in’ t Hout WG, Halma P, et al. Development and application of a radioreceptor assay for scopolamine. Arzneimittel Forschung 1988; 38: 106–11PubMedGoogle Scholar
  34. 34.
    Bosman IJ, Douma WR, Ensing K, et al. A semi-automated solid-phase extraction and radioreceptor assay for the analysis of scopolamine in urine and plasma. Eur J Pharm Sci 1997; 5: 315–25Google Scholar
  35. 35.
    Schmitt LG, Shaw JE, Carpenter PF, et al. Comparison of transdermal and intravenous administration of scopolamine [abstract]. Clin Pharmacol Ther 1981; 29: 282Google Scholar
  36. 36.
    Doweck I, Dachir S, Spitzer O, et al. Rate of absorption of scopolamine after application of Scopoderm-TTS [abstract]. Aviat Space Environ Med 1995; 66: 467Google Scholar
  37. 37.
    Doweck I, Nachum Z, Dachir S, et al. Enhancement of transdermal scopolamine absorption using sonophoresis [abstract]. In: Program and abstracts. 44th International Congress of Aviation and Space Medicine; 1996 Sep 8–13; JerusalemGoogle Scholar
  38. 38.
    Nachum Z, Shahal B, Shupak A, et al. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001; 296: 121–3PubMedGoogle Scholar
  39. 39.
    Cintron NM, Chen YM. A sensitive radioreceptor assay for determining scopolamine concentrations in plasma and urine. J Pharm Sci 1987; 76: 328–32PubMedGoogle Scholar
  40. 40.
    Gil A, Nachum Z, Dachir S, et al. Scopolamine patch to prevent seasickness: clinical response vs plasma concentration in sailors. Aviat Space Environ Med 2005; 76: 766–70PubMedGoogle Scholar
  41. 41.
    Attias J, Gordon C, Ribak J, et al. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea. Aviat Space Environ Med 1987; 58: 60–2PubMedGoogle Scholar
  42. 42.
    Nairn GJ. Transdermal therapeutic systems: scopolamine. Can J Hosp Pharm 1988; 41: 201–4Google Scholar
  43. 43.
    Dollenbacher U, Hofmann C, Vees G, et al. Pharmacokinetics of scopolamine in man after intravenous and transdermal application [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1986; 332 Suppl.: R93Google Scholar
  44. 44.
    Ostfeld A, Jenkins R, Pasnau R. Dose-response data for autonomic and mental effects of atropine and hyoscine [abstract]. Fed Proc 1959; 18: 430Google Scholar
  45. 45.
    Safer DJ, Allen RP. The central effects of scopolamine in man. Biol Psychiatry 1971; 3: 347–55PubMedGoogle Scholar
  46. 46.
    Price NM, Schmitt LG, McGuire J, et al. Transdermal scopolamine in the prevention of motion sickness at sea. Clin Pharmacol Ther 1981; 29: 414–9PubMedGoogle Scholar
  47. 47.
    Balkany TJ, Babin RW, Arenberg IK. Transdermal delivery of medications. Hosp Physician 1983; 19: 18–27Google Scholar
  48. 48.
    Cronin CM, Sallan SE, Wolfe L. Transdermal scopolamine in motion sickness. Pharmacotherapy 1982; 2: 29–31PubMedGoogle Scholar
  49. 49.
    Wood CD, Graybiel A. Theory of antimotion sickness drug mechanisms. Aerosp Med 1972; 43: 249–52PubMedGoogle Scholar
  50. 50.
    Larsen SB, Peitersen E. Scopoderm-TTS (scopolamine) influence on caloric-induced nystagmus: an extract. Adv Otorhinolaryngol 1983; 30: 365–9PubMedGoogle Scholar
  51. 51.
    Schmitt LG, Shaw JE, McGuire J, et al. Effect of drugs on vertigo induced by caloric irrigation of the external auditory canal [abstract]. Clin Pharmacol Ther 1981; 29: 282Google Scholar
  52. 52.
    Larsen SB, Peitersen E. Scopoderm-TTS (scopolamine) influence on caloric induced nystagmus [abstract]. Dan Med Bull 1983; 30: 127Google Scholar
  53. 53.
    Shojaku H, Watanabe Y, Ito M, et al. Effect of transdermally administered scopolamine on the vestibular system in humans. Acta Otolaryngol Suppl 1993; 504: 41–5PubMedGoogle Scholar
  54. 54.
    Pyykko I, Schalen L, Jantti V, et al. A reduction of vestibulovisual integration during transdermally administered scopolamine and dimenhydrinate: a presentation of gain control theory in motion sickness. Acta Otolaryngol Suppl 1984; 406: 167–73PubMedGoogle Scholar
  55. 55.
    Pyykko I, Schalen L, Matsuoka I. Transdermally administered scopolamine vs dimenhydrinate II: effect on different types of nystagmus. Acta Otolaryngol 1985; 99: 597–604PubMedGoogle Scholar
  56. 56.
    Pyykko I, Padoan S, Schalen L, et al. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat Space Environ Med 1985; 56: 777–82PubMedGoogle Scholar
  57. 57.
    Jaju BP, Kirsten EB, Wang SC. Effects of belladonna alkaloids on vestibular nucleus of the cat. Am J Physiol 1970; 219: 1248–55PubMedGoogle Scholar
  58. 58.
    Jaju BP, Wang SC. Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther 1971; 176: 718–24PubMedGoogle Scholar
  59. 59.
    Doweck I, Shupak A, Gordon CR, et al. The effects of transdermal scopolamine (TTS-Scopoderm) on the vestibulo-ocular reflex (VOR). In: Sterk W, Geeraedts L, editors. EUBS 1990 proceedings. Conference papers of the XVIth Annual Meeting of the European Undersea Biomedical Society, 1990, presented at the First Joint Meeting on Diving and Hyperbaric Medicine; 1990 Aug 11–18; Amsterdam. Amsterdam: Foundation for Hyperbaric Medicine, 1990: 271–6Google Scholar
  60. 60.
    Gowans J, Matheson A, Darlington CL, et al. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans. J Vestib Res 2000; 10: 87–92PubMedGoogle Scholar
  61. 61.
    Ali-Melkkila T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993; 37: 633–42PubMedGoogle Scholar
  62. 62.
    Golding JF, Stott JRR. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br J Clin Pharmacol 1997; 43: 633–7PubMedGoogle Scholar
  63. 63.
    Wackym PA, Chen CT, Ishiyama A, et al. Muscarinic acetylcholine receptor subtype mRNAs in the human and rat vestibular periphery. Cell Biol Int 1996; 20: 187–92PubMedGoogle Scholar
  64. 64.
    Gacek RR. Efferent innervation of the labyrinth. Am J Otolaryngol 1984; 5: 206–24PubMedGoogle Scholar
  65. 65.
    Morita M, Takeda N, Hasegawa S, et al. Effects of anti-cholinergic and cholinergic drugs on habituation to motion in rats. Acta Otolaryngol 1990; 110: 196–202PubMedGoogle Scholar
  66. 66.
    Ito J, Matsuoka I, Sasa M, et al. Electrophysiologic evidence for involvement of acetylcholine as a neurotransmitter in the lateral vestibular nucleus. Otolaryngol Head Neck Surg 1981; 89: 1025–9PubMedGoogle Scholar
  67. 67.
    Wamsley JK, Lewis MS, Young III WS, et al. Autoradiographic localization of muscarinic cholinergic receptors in rat brainstem. J Neurosci 1981; 1: 176–91PubMedGoogle Scholar
  68. 68.
    Wood CD, Stewart JJ, Wood MJ, et al. Habituation and motion sickness. J Clin Pharmacol 1994; 34: 628–34PubMedGoogle Scholar
  69. 69.
    Wood CD, Manno JE, Manno BR, et al. The effect of antimotion sickness drugs on habituation to motion. Aviat Space Environ Med 1986; 57: 539–42PubMedGoogle Scholar
  70. 70.
    Johnson P, Hansen D, Matarazzo D, et al. Transderm Scop patches for prevention of motion sickness [letter]. N Engl J Med 1984; 311: 468–9PubMedGoogle Scholar
  71. 71.
    Osterholm RK, Camoriano JK. Transdermal scopolamine psychosis [letter]. JAMA 1982; 247: 3081PubMedGoogle Scholar
  72. 72.
    Cairncross JG. Scopolamine psychosis revisited. Ann Neurol 1983; 13: 582PubMedGoogle Scholar
  73. 73.
    Rodysill KJ, Warren JB. Transdermal scopolamine and toxic psychosis [letter]. Ann Intern Med 1983; 98: 561PubMedGoogle Scholar
  74. 74.
    MacEwan GW, Remick RA, Noone JA. Psychosis due to transdermally administered scopolamine. CMAJ 1985; 133: 431–2PubMedGoogle Scholar
  75. 75.
    Ziskind AA. Transdermal scopolamine-induced psychosis. Postgrad Med 1988; 84: 73–6PubMedGoogle Scholar
  76. 76.
    Semple P, Madej TH, Wheatley RG, et al. Transdermal hyoscine with patient-controlled analgesia. Anaesthesia 1992; 47: 399–401PubMedGoogle Scholar
  77. 77.
    Checketts MR, Coventry DM. Transdermal hyoscine and confusion in the elderly [letter]. Anaesthesia 1992; 47: 1097PubMedGoogle Scholar
  78. 78.
    Sennhauser FH, Schwarz HP. Toxic psychosis from transdermal scopolamine in a child [letter]. Lancet 1986; II(8514): 1033Google Scholar
  79. 79.
    Johnson SF, Moore RJ. Transderm pupil and confusion in a 10 year old [letter]. Ann Neural 1983; 13: 583Google Scholar
  80. 80.
    Klein BL, Ashenburg CA, Reed MD. Transdermal scopolamine intoxication in a child. Pediatr Emerg Care 1985; 1: 208–9PubMedGoogle Scholar
  81. 81.
    Holland MS. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement. Nurse Anesth 1992; 3: 121–4PubMedGoogle Scholar
  82. 82.
    Gibbons PA, Nicolson SC, Betts EK, et al. Scopolamine does not prevent post-operative emesis after pediatric eye surgery. Anesthesiology 1984; 61: A435Google Scholar
  83. 83.
    Doyle E, Byers G, McNicol LR, et al. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. Br J Anaesth 1994; 72: 72–6PubMedGoogle Scholar
  84. 84.
    Saxena K, Saxena S. Scopolamine withdrawal syndrome. Postgrad Med 1990; 87: 63–6PubMedGoogle Scholar
  85. 85.
    Dahl E, Offer-Ohlsen D, Lillevold PE, et al. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther 1984; 36: 116–20PubMedGoogle Scholar
  86. 86.
    Gordon C, Binah O, Attias J, et al. Transdermal scopolamine: human performance and side effects. Aviat Space Environ Med 1986; 57: 236–40PubMedGoogle Scholar
  87. 87.
    Hordinsky JR, Schwartz E, Beier J, et al. Relative efficacy of the proposed space shuttle antimotion sickness medications. Acta Astronaut 1982; 9: 375–83PubMedGoogle Scholar
  88. 88.
    McCauley ME, Royal JW, Shaw JE, et al. Effect of transdermally administered scopolamine in preventing motion sickness. Aviat Space Environ Med 1979; 50: 1108–11PubMedGoogle Scholar
  89. 89.
    Dibner-Dunlap ME, Eckberg DL, Magid NM. Transcutaneous scopolamine: a potential defense against sudden cardiac death [abstract]. Clin Res 1984; 32: 473AGoogle Scholar
  90. 90.
    Parrott AC. The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance. Psychopharmacology 1986; 89: 347–54PubMedGoogle Scholar
  91. 91.
    Parrott AC. Transdermal scopolamine: effects of single and repeated patches upon psychological task performance. Neuropsychobiology 1987; 17: 53–9PubMedGoogle Scholar
  92. 92.
    Scheurlen M, Antonin K-H, Bieck PR. Effect of low-dose anticholinergic treatment with transdermal scopolamine (Transderm™ V) on gastric acid secretion [abstract]. Scand J Gastroenterol Suppl 1982; 78: 112Google Scholar
  93. 93.
    Parrott AC. Transdermal scopolamine: effects of single and repeated patches upon aspects of vision. Hum Psychopharmacol 1986; 1: 109–15Google Scholar
  94. 94.
    Parrott AC. Transdermal scopolamine: effects upon psychological performance and visual functioning at sea. Hum Psychopharmacol 1988; 3: 119–25Google Scholar
  95. 95.
    Alhalel A, Ziv I, Versano D, et al. Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. Aviat Space Environ Med 1995; 66: 1037–40PubMedGoogle Scholar
  96. 96.
    Herxheimer A. A comparison of some atropine-like drugs in man, with particular reference to their end-organ specificity. Br J Pharmacol Chemother 1958; 13: 184–92PubMedGoogle Scholar
  97. 97.
    Mirakhur RK. Comparative study of the effects of oral and i.m. atropine and hyoscine in volunteers. Br J Anaesth 1978; 50: 591–8PubMedGoogle Scholar
  98. 98.
    Glaser EM. Experiments on side-effects of drugs. Br J Pharmacol Chemother 1953; 8: 187–92PubMedGoogle Scholar
  99. 99.
    Lepore FE. More on cycloplegia from transdermal scopolamine [letter]. N Engl J Med 1982; 307: 824PubMedGoogle Scholar
  100. 100.
    Babin RW, Balkany TJ, Fee WE. Transdermal scopolamine in the treatment of acute vertigo. Ann Otol Rhinol Laryngol 1984; 93: 25–7PubMedGoogle Scholar
  101. 101.
    Longo DL, Wesley M, Howser D, et al. Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatininduced emesis. Cancer Treat Rep 1982; 66: 1975–6PubMedGoogle Scholar
  102. 102.
    Patterson JH, Ives TJ, Greganti MA. Transient bilateral pupillary dilation from scopolamine discs [letter]. Drug Intell Clin Pharm 1986; 20: 986–7PubMedGoogle Scholar
  103. 103.
    Rosen NB. Accidental mydriasis from scopolamine patches. J Am Optom Assoc 1986; 57: 541–2PubMedGoogle Scholar
  104. 104.
    Good WV, Crain LS. Esotropia in a child treated with a scopolamine patch for drooling. Pediatrics 1996; 97: 126–7PubMedGoogle Scholar
  105. 105.
    Carlston JA. Unilateral dilated pupil from scopolamine disk [letter]. JAMA 1982; 248: 31PubMedGoogle Scholar
  106. 106.
    Chiaramonte JS. Cycloplegia from transdermal scopolamine [letter]. N Engl J Med 1982; 306: 174PubMedGoogle Scholar
  107. 107.
    McCrary III JA, Webb NR. Anisocoria from scopolamine patches. JAMA 1982; 248: 353–4PubMedGoogle Scholar
  108. 108.
    Price BH. Anisocoria from scopolamine patches [letter]. JAMA 1985; 253: 1561PubMedGoogle Scholar
  109. 109.
    Bienia RA, Smith M, Pellegrino T. Scopolamine skin-disks and anisocoria [letter]. Ann Intern Med 1983; 99: 572–3PubMedGoogle Scholar
  110. 110.
    Roper DL, Hale LL. A case report: unilateral cycloplegia resulting from careless use of Transderm-V. Aviat Space Environ Med 1982; 53: 1129–30PubMedGoogle Scholar
  111. 111.
    Verdier DD, Kennerdell JS. Fixed dilated pupil resulting from transdermal scopolamine [letter]. Am J Ophthalmol 1982; 93: 803–4PubMedGoogle Scholar
  112. 112.
    Hodgson T. Preventing motion sickness [letter]. CMAJ 1982; 126: 1374Google Scholar
  113. 113.
    Rubin MM, Sadoff RS, Cozzi GM. Unilateral mydriasis caused by transdermal scopolamine. Oral Surg Oral Med Oral Pathol 1990; 70: 569–70PubMedGoogle Scholar
  114. 114.
    Thiele EA, Riviello JJ. Scopolamine patch-induced unilateral mydriasis. Pediatrics 1995; 96: 525PubMedGoogle Scholar
  115. 115.
    Fraunfelder FT. Transdermal scopolamine precipitating narrow-angle glaucoma [letter]. N Engl J Med 1982; 307: 1079PubMedGoogle Scholar
  116. 116.
    Gordon C, Ben-Aryeh H, Attias J, et al. Effect of transdermal scopolamine on salivation. J Clin Pharmacol 1985; 25: 407–12PubMedGoogle Scholar
  117. 117.
    van Marion WF, Bongaerts MCM, Christiaanse JC, et al. Influence of transdermal scopolamine on motion sickness during 7 days’ exposure to heavy seas. Clin Pharmacol Ther 1985; 38: 301–5PubMedGoogle Scholar
  118. 118.
    Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary flow with transdermal scopolamine: a four-year experience. Otolaryngol Head Neck Surg 1990; 103: 615–8PubMedGoogle Scholar
  119. 119.
    Lewis DW, Fontana C, Mehallick LK, et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol 1994; 36: 484–6PubMedGoogle Scholar
  120. 120.
    Jongerius PH, van den Hoogen FJ, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004; 114: 620–7PubMedGoogle Scholar
  121. 121.
    Turner P. Tests of autonomie function in assessing centrally-acting drugs. Br J Clin Pharmacol 1980; 10: 93–9PubMedGoogle Scholar
  122. 122.
    Patterson T, Venables PH. Bilateral skin conductance and the pupillary light-dark reflex: manipulation by chlorpromazine, haloperidol, scopolamine, and placebo. Psychopharmacol Berl 1981; 73: 63–9Google Scholar
  123. 123.
    Gordon CR, Shupak A, Doweck I, et al. Allergic contact dermatitis caused by transdermal hyoscine. BMJ 1989; 298: 1220–1PubMedGoogle Scholar
  124. 124.
    Kanto J, Kentala E, Kaila T, et al. Pharmacokinetics of scopolamine during caesarean section: relationship between serum concentration and effect. Acta Anaesthesiol Scand 1989; 33: 482–6PubMedGoogle Scholar
  125. 125.
    Ayromlooi J, Tobias M, Berg P. The effects of scopolamine and ancillary analgesics upon the fetal heart rate recording. J Reprod Med 1980; 25: 323–6PubMedGoogle Scholar
  126. 126.
    Evens RP, Leopold JC. Scopolamine toxicity in a newborn [letter]. Pediatrics 1980; 66: 329–30PubMedGoogle Scholar
  127. 127.
    Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation, a reference guide to fetal and neonatal risk. 4th ed. Baltimore (MD): Williams & Wilkins, 1994: 777–8Google Scholar
  128. 128.
    Deutsch JA. The cholinergic synapse and the site of memory. Science 1971; 174: 788–94PubMedGoogle Scholar
  129. 129.
    Warburton DM, Wesnes K. Drugs as research tools in psychology: cholinergic drugs and information processing. Neuropsychobiology 1984; 11: 121–32PubMedGoogle Scholar
  130. 130.
    Nissen MJ, Knopman DS, Schacter DL. Neurochemical dissociation of memory systems. Neurology 1987; 37: 789–94PubMedGoogle Scholar
  131. 131.
    Robbins TW, Semple J, Kumar R, et al. Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: comparison with diazepam and implications for dementia. Psychopharmacology Berl 1997; 134: 95–106PubMedGoogle Scholar
  132. 132.
    Rosier A, Cornette L, Orban GA. Scopolamine-induced impairment of delayed recognition of abstract visual shapes. Neuropsychobiology 1998; 37: 98–103PubMedGoogle Scholar
  133. 133.
    Wood CD, Manno JE, Manno BR, et al. Side effects of antimotion sickness drugs. Aviat Space Environ Med 1984; 55: 113–6PubMedGoogle Scholar
  134. 134.
    Ketchum JS, Sidell FR, Crowell Jr EB, et al. Atropine, scopolamine, and ditran: comparative pharmacology and antagonists in man. Psychopharmacologia 1973; 28: 121–45PubMedGoogle Scholar
  135. 135.
    Gleiter CH, Antonin KH, Bieck PR. Transdermally applied scopolamine does not impair psychomotor performance. Psychopharmacology Berl 1984; 83: 397–8PubMedGoogle Scholar
  136. 136.
    Gordon CR, Gonen A, Nachum Z, et al. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 2001; 15: 167–72PubMedGoogle Scholar
  137. 137.
    Noy S, Shapira S, Zilbiger A, et al. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo: a comparative study at sea. Aviat Space Environ Med 1984; 55: 1051–4PubMedGoogle Scholar
  138. 138.
    Shupak A, Gordon CR, Spitzer O, et al. Three-years’ experience of transdermal scopolamine: long-term effectiveness and side-effects. Pharmatherapeutica 1989; 5: 365–70PubMedGoogle Scholar
  139. 139.
    Nachum Z, Tal D, Shupak A. A comparison of transdermal scopolamine and cinnarizine for the prevention of seasickness [abstract]. Aviat Space Environ Med 2001; 72: 276Google Scholar
  140. 140.
    Sitaram N, Moore AM, Gillin JC. Scopolamine-induced muscarinic supersensitivity in normal man: changes in sleep. Psychiatry Res 1979; 1: 9–16PubMedGoogle Scholar
  141. 141.
    Innes IR, Nickerson M. Atropine, scopolamine, and related antimuscarinic drugs. In: Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 5th ed. New York: Macmillan, 1975: 514–32Google Scholar
  142. 142.
    Kim EJ, Jeong DU. Transdermal scopolamine alters phasic REM activity in normal young adults. Sleep 1999; 22: 515–20PubMedGoogle Scholar
  143. 143.
    Spinks AB, Wasiak J, Villanueva EV, et al. Scopolamine for preventing and treating motion sickness. Cochrane Database Syst Rev 2004; (3): CD002851PubMedGoogle Scholar
  144. 144.
    Wood MJ, Wood CD, Stewart JJ, et al. Comparison of dosage routes for antimotion sickness drugs [abstract]. Aviat Space Environ Med 1987; 58: 504Google Scholar
  145. 145.
    Levy GD, Rapaport MH. Transderm scopolamine efficacy related to time of application prior to the onset of motion. Aviat Space Environ Med 1985; 56: 591–3PubMedGoogle Scholar
  146. 146.
    How J, Lee P-S, Seet L-C, et al. The Republic of Singapore Navy’s Scopoderm TTS study: results after 2,200 man-days at sea. Aviat Space Environ Med 1988; 59: 646–50PubMedGoogle Scholar
  147. 147.
    Schmid R, Schick T, Steffen R, et al. Comparison of seven commonly used agents for prophylaxis of seasickness. J Travel Med 1994; 1: 203–6PubMedGoogle Scholar
  148. 148.
    Kroll JD. Control of simulator sickness in an AH-64 aviator. Aviat Space Environ Med 1989; 60: 1202–3PubMedGoogle Scholar
  149. 149.
    Landolt JP, Monaco C. Seasickness in totally-enclosed motor-propelled survival craft: remedial measures. Aviat Space Environ Med 1992; 63: 219–25PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Zohar Nachum
    • 1
    • 2
    Email author
  • Avi Shupak
    • 1
    • 3
  • Carlos R. Gordon
    • 1
    • 4
  1. 1.Motion Sickness and Human Performance Laboratory, Israel Naval Medical InstituteIDF Medical CorpsHaifaIsrael
  2. 2.Department of Obstetrics and GynecologyHa’Emek Medical CenterAfulaIsrael
  3. 3.Department of Otolaryngology-Head and Neck Surgery, Carmel Medical Center and the Otoneurology UnitLin Medical CenterHaifaIsrael
  4. 4.Department of Neurology, Meir General Hospital, Kfar Saba and Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations